Health Is Not A Business

By Carlos Herrero Carcedo

Governments should regain responsibility for defining the lines of investment in research for medicines, since they are public goods, and to manage the basic research phase, disassociating them from production, distribution and sale.
The transatlantic trade and investment partnership (TTIP) between the EU and US will allow a more permissive european regulation on health and food for benefit of multinationals and to the detriment of european citizens.

• Language: English
• Publisher: Carlos Herrero Carcedo
• Release date: Jan 1, 2017

Carlos Herrero Carcedo

Autor de dos Libros con tapa: Manual Básico de Farmacología y 200 Ideas para Mejorar la Rentabilidad de tu Farmacia, una publicación en la revista Alimentación, Equipos y Tecnología: La histamina en las distintas etapas de fabricación de conservas de atún y seis Ebooks: Disruptores Endocrinos, La Salud no es un Negocio, Obesidad Infantil. Rista. Respuesta Insuficientemente Adecuada, Vivir sin Cáncer, Ser Mayor sin Edad y Predisposición a Ser Homosexual.Posee tres licenciaturas (Farmacia, Ciencias Químicas, Ciencia y Tecnología de los Alimentos) y experiencia en los departamentos de Calidad, Producción y Ventas.

Book preview

HEALTH

IS NOT

A BUSINESS

Carlos Herrero Carcedo

www.carlosherrerocarcedo.com

HEALTH IS NOT A BUSINESS

Carlos Herrero Carcedo

www.carlosherrerocarcedo.com

Copyright© 2020 by Carlos Herrero Carcedo

All rights reserved

LEGAL WARNING

It is strictly prohibited without the written permission of the copyright holder, the reproduction of this work by any means or process including reprography and computer processing.

TABLE OF CONTENTS

1.Investment in Pharmaceutical Multinational Research.

2.Therapeutic Contract Responsibility.

3.TTIP and Pharmaceutical Industry.

4.Transatlantic Trade and Investment Partnership(TTIP).

5.TTIP and Food Industry.

6.Lobbies in the European Union.

7.Endocrine Disruptors.

8.Other Books of the Author

1.Investment in Pharmaceutical Multinational Research.

The current system of research and development of new drugs is contrary to the health of the population in general. Only one out every five drugs on the market is innovative or improves the results of the previous ones. The problem is eightened as these new molecules are priced high and there is no official organization that ensures that these drugs are affordable for those who need them. Governments have allowed the pharmaceutical industry to decide which diseases to address and how many patients to treat. According to the World Health Organization, one third of people do not have regular access to medicines. If the production capacity exists, it will be the cost of the drug to determine the number of patients who die (the treatment of several weeks of sofosbuvir for hepatitis C costs 60,000 euros).

Governments finance 80% of basic research of therapeutic molecules, which is done at universities, hospitals and public centers, and pharmaceutical laboratories develop the ideas found by scientists from these public institutions at a cost of less than 8% of their billing. In fact, the final